June 13th 2025
Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.
Ketamine May Give 'Almost Instantaneous' Relief for Severe Depression
August 7th 2006BETHESDA, Md. -- Symptoms of depression can be made to disappear in less than two hours with a common anesthetic, not the weeks or months required for onset of relief with traditional antidepressants, according to results of a pilot study.
Why We Need to Know the Limitations of Evidence-Based Medicine
August 1st 2006Primary care clinicians are encouraged to use the latest evidence-based diagnostic and therapeutic strategies from prospective randomized, controlled trials in their practice. But are the participants in these trials typical patients?
Monitoring adolescents with cystic fibrosis
July 1st 2006abstract: There is increasing evidence that close monitoring and early intervention lead to better outcomes in patients with cystic fibrosis. At each office visit, spirometry should be performed and sputum culture specimens should be obtained; if the patient cannot produce sputum, a throat culture can be done instead. New respiratory symptoms or other evidence of worsening lung disease should prompt antibiotic therapy, increased airway clearance, and adjunctive anti-inflammatory medication as appropriate. Close attention should be paid to the patient's diet, appetite, stooling pattern, and growth measurements. Adolescents should be given additional information about their medications and adjunctive therapies to encourage them to take on a larger role in their own care. (J Respir Dis.2006;27(7):298-305)
Woman With Nausea, Emesis, and Abdominal Pain After Splenic Artery Embolization
July 1st 2006A 68-year-old woman presents with recurrent nausea, vomiting, left upper quadrant pain, decreased appetite, and a 2.3-kg (5-lb) weight loss 1 month after she underwent selective splenic artery embolization for refractory thrombocytopenia secondary to hypersplenism.
ADA: Investigational Drug Produces Significant Weight Loss for Obese
June 13th 2006WASHINGTON - Lorcaserin, an investigational drug for the treatment of obesity, was successful at producing weight loss ranging between four and 7.9 pounds (1.8 to 3.6 kg) in a 12-week study, reported investigators here.
FDA Approves First Drug for Treatment of Seasonal Affective Disorder
June 12th 2006ROCKVILLE, Md. - The FDA today approved Wellbutrin XL (bupropion extended release) for prevention of major depressive episodes in patients with a history of seasonal affective disorder (SAD). It is the first drug approved for SAD.